FridayMay 14, 2021 2:50 pm

An Infant’s First Stool May Be Used to Predict Their Future Health

A recent study by a group of researchers from the University of British Columbia has found that the composition of meconium can be used to find out whether a baby will develop allergies as they get older. Meconium, which is a child’s first poop, is a thick dark-green substance. The research was reported in the Cell Reports Medicine journal. Dr. Brett Finlay, a professor from the university’s departments of immunology, microbiology, molecular biology and biochemistry, explained that the analysis they conducted showed that compared with babies who didn’t develop allergic sensitization, those who did had considerably less rich meconium after…

Continue Reading

FridayMay 14, 2021 12:25 pm

RYAH Group Inc. (CSE: RYAH) Releases “April 2021 Patients Patterns in New York Report” to Provide Data-Driven Insights Amid Latest Legislation Change

RYAH has released April 2021 Patients Patterns in New York Report to bring invaluable data-driven insights within the plant-based health industry amid recent recreational cannabis legislation change in this state. The company leveraged data from 4,387 New York patients within the RYAH Data ecosystem to discover New York-based patients' profiles, including their preferences and medical reasons for use. As an authority in dose-control technology for plant-based medicine, RYAH appears well placed to capitalize on growing market opportunities. RYAH Group (CSE: RYAH) (formerly known as Prime Blockchain Inc.) has announced the release of its "April 2021 Patients Patterns in New York…

Continue Reading

FridayMay 14, 2021 12:04 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update

April analyst reports all point to a bright future for Cybin “CYBN is a true multi-molecule company that's not being reflected in its valuation,” reports Stifel “With a relatively small 5% penetration, Cybin could achieve ~$8B in sales in the U.S. and EU5 combined,” notes Roth A series of recent analyst reports bodes well for Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics. April reports from Canaccord Genuity equity research company, Stifel GMP (https://ibn.fm/aQ9af) and Roth Capital Partners (https://ibn.fm/YkBNb) all categorize Cybin as a buy, with Stifel increasing its price target from $5 to…

Continue Reading

ThursdayMay 13, 2021 1:22 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Working Towards a Better Future for Bladder Cancer Patients

Bladder cancer is still the sixth most prevalent cancer in the U.S. in 2021 The total number of new bladder cancer cases is expected to reach 83,730, with deaths totaling 17,200 this year Imagin Medical Inc. is hoping to offer a better standard of care for bladder cancer patients with its i/Blue Imaging System(TM) that improves visualization for resection, potentially lowering recurrence rates According to American Cancer Society statistics, the number of cases of all types of cancer this year will total almost 1.9 million, with 608,570 deaths, or approximately 5,200 new cases and 1,670 deaths per day (https://ibn.fm/eDdCz). Of…

Continue Reading

ThursdayMay 13, 2021 12:05 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders

Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia The company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptoms Tryp has announced two new collaborations for oversight of the drug trials this month; consultants with Fluence and Clinlogix will help to ensure the quality of the tests Bioscience pharmaceutical company Tryp Therapeutics (CSE:…

Continue Reading

ThursdayMay 13, 2021 11:16 am

Fasting Reduces Blood Pressure, Restructures Gut Microbiome, Study Finds

A study conducted by researchers from Baylor College of Medicine has found that intermittent fasting (“IF”) has the potential to decrease hypertension by restructuring gut microbiome. Hypertension increases an individual’s risk for getting a stroke or cardiovascular ailments, which are the major causes of death within the United States. The objective of the team of researchers who conducted the study was to learn more about hypertension and, more specifically, about the evidence that suggested that blood pressure could increase if gut microbiota is disrupted in a process called gut dysbiosis. The team included Baylor professor of anesthesiology Dr. David Durgan,…

Continue Reading

WednesdayMay 12, 2021 11:36 am

Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) on Schedule for Completion in 2022 

Imagin Medical’s contract manufacturer, Lighthouse Imaging, has developed a program focused on refining the i/Blue System’s design for manufacturing Lighthouse’s manufacturing process will ensure that regulatory standards are followed while maintaining optimal performance and staying within targeted costs Imagin is currently focusing on using the i/Blue system for bladder cancer visualization with plans to extend the use of the technology to other procedures in the future Imagin Medical (CSE: IME) (OTCQB: IMEXF) is on track to complete its patented i/Blue Imaging System(TM) in 2022. The innovative technology leverages proprietary light sensors and optics to improve the accuracy and efficiency of…

Continue Reading

WednesdayMay 12, 2021 11:16 am

Healthy Extracts Inc. (HYEX) Announces Association Of Dr. Kahn With The Healthy Extracts Inc. Medical Board

Healthy Extracts Inc. announces the addition of Dr. Joel Kahn, M.D., a world-renowned, triple board-certified cardiology specialist to its medical board Dr. Kahn has personally conducted clinical studies that confirm the benefits of Citrus Bergamot SuperFruit(TM) for cardiovascular health Citrus Bergamot SuperFruit(TM), the main ingredient in BergametNA’s product line, is the super fruit alternative to prescribed cholesterol medications Healthy Extracts (OTCQB: HYEX), through its developing and acquiring complementary companies, is engaged in manufacturing plant-based formulations dedicated to heart and Brain health. With its focus towards strengthening its position in the multibillion-dollar nutraceuticals market, the company has already launched its science-based BergaMet North…

Continue Reading

WednesdayMay 12, 2021 11:14 am

New Experimental Drug Reverses Crucial Alzheimer’s Symptoms

Scientists from the Albert Einstein College of Medicine have developed an experimental medication that reverses the major symptoms of Alzheimer’s disease. The researchers, who used mice for their research, found that the medication revitalized a cellular cleaning mechanism that eliminates unwanted proteins by recycling and digesting them. The research was reported in the “Cell” journal. Ana Maria Cuervo, a professor and a study leader, explained that while discoveries in mice didn’t always play out the same way in human beings, the researchers were encouraged to learn that the cell-cleaning process that they had observed in mice also occurred in patients…

Continue Reading

TuesdayMay 11, 2021 2:36 pm

Brain Scientific Inc. (BRSF) Releases 2020 Financial, Business Results

BRSF made strides on operations front to improve lead times, quality control Company experienced revenue growth, increase in assets and R&D Brain Scientific has identified that only 30% of U.S. hospitals have equipment for routine EEGs due to cost and space constraints Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, announced it has filed its annual report for the fiscal year that ended Dec. 31, 2020 (https://ibn.fm/GCazt). The company reported key business highlights and substantial growth as well as outlined milestones expected to be completed over the next two years. “In 2020, Brain Scientific made good progress toward our vision of…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050